share_log

Chardan Capital Maintains Buy on Senti Biosciences, Raises Price Target to $12

Chardan Capital Maintains Buy on Senti Biosciences, Raises Price Target to $12

Chardan Capital維持對Senti Biosciences的買入評級,將目標價格上調至12美元。
Benzinga ·  12/04 04:21

Chardan Capital analyst Geulah Livshits maintains Senti Biosciences (NASDAQ:SNTI) with a Buy and raises the price target from $10 to $12.

Chardan Capital分析師Geulah Livshits維持對Senti Biosciences(納斯達克:SNTI)的買入評級,並將目標價格從10美元上調至12美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論